DPYD基因型指导剂量个体化以改善氟尿嘧啶治疗安全性:呼吁更新药品标签
氟尿嘧啶类药物(5-FU和卡培他滨)广泛用于多种癌症,但部分患者因DPD酶活性降低而出现严重毒性。DPYD基因多态性是DPD缺陷的主要原因,4个DPYD变异(DPYD*2A、c.2846A>T、c.1679T>G、c.1236G>A)的功能和临床有效性已确立。预先筛查DPYD基因型并对杂合携带者进行剂量调整可显著改善患者安全,呼吁更新药品标签。
要点
- DPYD基因多态性导致部分DPD缺陷,增加氟尿嘧啶严重毒性风险。
- 4个DPYD变异(DPYD*2A、c.2846A>T、c.1679T>G、c.1236G>A)与毒性风险增加相关。
- 预先筛查DPYD基因型并对杂合携带者剂量调整可改善安全性。
核心结论
- 基于现有数据的严格评估,在卡培他滨和5-FU药品标签中加入DPYD变异预先筛查和DPYD基因型指导剂量调整的建议应成为新的标准治疗。
研究设计与样本
- 本文为呼吁更新药品标签的综述性文章,基于对现有数据的严格评估,未报告系统检索范围。
主要发现
- 估计3%-8%的人群存在部分DPD缺陷。
- 4个DPYD变异(DPYD*2A、c.2846A>T、c.1679T>G、c.1236G>A)的功能和临床有效性已确立,回顾性和大规模人群前瞻性研究显示与氟尿嘧啶相关毒性风险增加相关。
- 预先筛查DPYD基因型并对杂合DPYD变异等位基因携带者进行剂量调整可显著改善氟尿嘧啶治疗的患者安全,使5-FU暴露正常化。
关键数值与推荐
- 原文未报告具体的剂量调整方案或推荐等级。
临床怎么用
- 原文建议在卡培他滨和5-FU药品标签中加入DPYD变异预先筛查和DPYD基因型指导剂量调整的推荐,并认为应成为新的标准治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and capecitabine in the European Union and the United States, no adaptive dosing strategies are incorporated for polymorphic metabolism of 5-FU. Although treatment with fluoropyrimidines is generally well tolerated, a major clinical limitation is that a proportion of the treated population experiences severe, sometimes life-threatening, fluoropyrimidine-related toxicity. This toxicity is strongly affected by interindividual variability in activity of dihydropyrimidine dehydrogenase (DPD), the main metabolic enzyme for inactivation of fluoropyrimidines, with an estimated 3%-8% of the population being partially DPD deficient. A reduced functional or abrogated DPD enzyme is often caused by genetic polymorphisms in DPYD, the gene encoding for DPD, and heterozygous carriers of such DPYD polymorphisms have a partial DPD deficiency. When these partially DPD deficient patients are treated with a full dose of fluoropyrimidines, they are generally exposed to toxic levels of 5-FU and its metabolites, and the risk of developing severe treatment-related toxicity is therefore significantly increased.Currently, functional and clinical validity is well established for four DPYD variants (DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A), as those variants have retrospectively and in a large population study prospectively been shown to be associated with increased risk of fluoropyrimidine-associated toxicity. Patient safety of fluoropyrimidine treatment can be significantly improved by pre-emptive screening for DPYD genotype variants and dose reductions in heterozygous DPYD variant allele carriers, thereby normalizing 5-FU exposure. Based on the critical appraisal of currently available data, adjusting the labels of capecitabine and 5-FU by including recommendations on pre-emptive screening for DPYD variants and DPYD genotype-guided dose adjustments should be the new standard of care.
引用
- Henricks LM, Opdam FL, Beijnen JH, et al. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol. 2017. PMID: 29045513. doi:10.1093/annonc/mdx411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。